Woburn, MA – July 28, 2021 – MBL International, a JSR Life Sciences company, recently announced commercial availability of QuickSwitch™ Class II Custom MHC Tetramer Kits. QuickSwitch kits for Class II MHC Tetramers for analysis of CD4+ T cells have been created to meet the needs of scientists looking for better understanding of the CD4+ T cell responses.

New Vice President to lead North America and Europe Business Development

Geneva, Switzerland, and Durham, NC – June 29, 2021  – Selexis SA and KBI Biopharma (KBI), both JSR Life Sciences companies, announced today that they have signed service agreements with Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies. The agreements focus on using integrated services from Selexis and KBI as part of Immatics’ development of TCR Bispecifics, called TCER^® (T Cell Engaging Receptors), that simultaneously recruit, activate and stimulate the patient’s own T cells to detect, target and attack tumor cells. Under the agreements, Selexis will utilize its SUREtechnology Platform™ and KBI will leverage its advanced analytics, process, formulation and cGMP manufacturing for Immatics’ IMA402 program. 

Agreement supports future commercial manufacturing for AM-Pharma’s recombinant alkaline phosphatase program

Utrecht, The Netherlands and DURHAM, NC – June 17, 2021 – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, and AM-Pharma, an emerging leader focused on the development of therapeutics that protect organ function in patients with severe medical conditions, have signed a commercial manufacturing agreement to advance AM-Pharma’s recombinant human Alkaline Phosphatase (recAP) program towards commercialization. AM-Pharma is developing recAP for the potential treatment of Sepsis-Associated Acute Kidney Injury (SA-AKI). 

Acquisition augments CrownBio’s preclinical in vitro service platforms, adding high content imaging and advanced tumor organoid analytics to three-dimensional immuno-oncology drug assays

San Diego, California, May 5, 2021 – Crown Bioscience (CrownBio), a JSR Life Sciences company and leader in preclinical services that help biopharmaceutical companies accelerate new drug development programs, has acquired OcellO B.V., a privately owned contract research

Company Appoints Seasoned Life Science Investment and Business Development Executive
Dr. Jason Yuanxin Zhang to Lead the Fund

SUNNYVALE, California, March 23, 2021 – JSR Life Sciences, LLC today announced the launch of its ‘JSR Life Sciences Corporate Venture Fund.’ As part of a continued effort to identify and accelerate novel therapies and innovative technologies, JSR will leverage the new fund to invest in multiple deals within the next few years.